PROVIDES A PROTECTIVE ENVIRONMENT TO SUPPORT THE HEALING CASCADE

• Derived from Human Umbilical Cord

• Comprised of an Extracellular Matrix of Hyaluronic Acid and Collagen

• Contains 250+ Regulatory Proteins1-2

EC151.001

Hyaluronic Acid Hydrates and Reinforces Collagen

Hyaluronic Acid

Collagen

2 cm x 3 cm Expands to 12 cm2

NEW SIZE!1 cm x 2 cm NOW AVAILABLE

Hyaluronic Acid (HA) can hold up to 1000 times its weight in water. As a primary component in the umbilical cord, natural HA hydrates, forming a reinforced matrix to support the wound healing cascade.5-6

Role of Hyaluronic Acid in Wounds

The ONLY CLINICALLY PROVEN Expandable Dehydrated Human Umbilical Cord Allograft3-4

Patents and patents pending see: www.mimedx.com/patents. EPICORD, PURION, SMR2T, and MIMEDX are trademarks of MIMEDX Group, Inc. ©2021 MIMEDX Group, Inc. All Rights Reserved. www.mimedx.com EC151.001

Patient Insurance Verification Team:855.882.8480

Clinical Use Examples• Smaller, deeper wounds• Thick graft allows for

suturing to keep the graft in place

• All EPICORD configurations conform to uneven surfaces

• EPICORD Expandable 2 cm x 3 cm expands to 12 cm2

Product Advantages• EPICORD RCT Level I Data*• SMR2TTM Technology• PURION Process• Terminal Sterilization• Easy to Apply• Room Temperature Storage• 5-year shelf life

866.477.4219 • customerservice@mimedx.com

*Identified as low risk-of-bias RCT in 2020 Skin Substitute Technical Assessment by Agency for Healthcare Research and Quality

A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EPICORD) allograft for the treatment of DFUs7

Wound Closure Rates at 12 Weeks in Diabetic Foot Ulcer (DFU) Patients with EPICORD vs. Standard Care7

ITEM # SPECIFICATIONSAREA

WITHOUT EXPANSION

PREDICTED EXPANSION

DIMENSIONSQ CODE

EC-5120 EPICORD 1 cm x 2 cm 2 cm2 N/A Q4187

EC-5230 EPICORD 2 cm x 3 cm 6 cm2 N/A Q4187

EC-5350 EPICORD 3 cm x 5 cm 15 cm2 N/A Q4187

EX-5230EPICORD

EXPANDABLE 2 cm x 3 cm

6 cm2 12 cm2 (4 cm x 3 cm) Q4187

NEW SIZE

Intent-to-Treat With Adequate DebridementPer-Protocol (PP)

n=134Intent-to-Treat (ITT)

n=155 n=107100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%Control (SC) Control (SC) Control (SC)

n=86 n=67n=48 n=40n=54EPICORD + SC EPICORD + SC EPICORD + SC

n=101

81%

54%

70%

48%

p = 0.0089

p = 0.0013

p < 0.000196%

65% Additional Kaplan-Meier analysis on the ITT population showed subjects treated with EPICORD had a superior wound closure trajectory at 12 weeks compared to Control (p=0.0152)

EPICORD Configurations

REFERENCES 1. MM-RD-00086, Proteome Characterization of PURION Processed Dehydrated Human Amnion Chorion Membrane (dHACM) and PURION Plus Processed Dehydrated Human Umbilical Cord (dHUC) Allografts. 2. Bullard JD, Lei J, Lim JJ, Massee M, Fallon AM, Koob TJ. Evaluation of dehydrated human umbilical cord biological properties for wound care and soft tissue healing. J Biomed Mater Res B Appl Biomater. 2019;107(4):1035-1046. 3. ECX121.001, MIMEDX Case Study, Mixed Venous and Arterial RLE Ulcer Treated with EPICORD EXPANDABLE 4. ECX117.001, MIMEDX Case Study, The Use of EPICORD in Patients With Chronic Wounds and Concurrent Comorbidities 5. Sakamoto T, Ono H, Saito Y. Nihon Sanka. Electron microscopic histochemical studies on the localization of hyaluronic acid in Wharton’s jelly of the human umbilical cord. Nihon Sanka Fujinka Gakkai Zasshi. 1996;48(7):501-507. 6. Sobolewski K, Bańkowski E, Chyczewski L, Jaworski S. Collagen and glycosaminoglycans of Wharton’s jelly. Biol Neonate. 1997;71(1):11-21. 7. Tettelbach W, Cazzell S, Sigal F, et al. A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers. Int Wound J. 2019;16(1):122-130.

EC-5120 EC-5230

EC-5350

EX-5230

NEW SIZE

2 cm x 3 cm expands to 12 cm2

Closu

re W

ithin

12 W

eeks